127 related articles for article (PubMed ID: 38420798)
1. The Role of
Chu J; Tang S; Li T; Fan H
Front Biosci (Landmark Ed); 2024 Feb; 29(2):73. PubMed ID: 38420798
[TBL] [Abstract][Full Text] [Related]
2. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
3. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
5. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
7. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract][Full Text] [Related]
8. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
[TBL] [Abstract][Full Text] [Related]
9. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
Hu XE; Yang P; Chen S; Wei G; Yuan L; Yang Z; Gong L; He L; Yang L; Peng S; Dong Y; He X; Bao G
Breast Cancer Res; 2023 Mar; 25(1):34. PubMed ID: 36998014
[TBL] [Abstract][Full Text] [Related]
13. Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.
Wu M; Yuan K; Lyu S; Li Y
World J Surg Oncol; 2022 Jun; 20(1):214. PubMed ID: 35751103
[TBL] [Abstract][Full Text] [Related]
14. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
Vishnubalaji R; Alajez NM
Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
[TBL] [Abstract][Full Text] [Related]
16. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
[TBL] [Abstract][Full Text] [Related]
18. Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer.
Shi Y; Huang X; Du Z; Tan J
Math Biosci Eng; 2022 Apr; 19(6):5793-5812. PubMed ID: 35603379
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
20. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]